Correspondence 0001628908-24-000103 from Evolent Health, Inc. (EVH)
Evolent Health, Inc.
Date: Oct. 4, 2024 · CIK: 0001628908 · Accession: 0001628908-24-000103
AI Filing Summary & Sentiment
File numbers found in text: 001-37415
Referenced dates: September 20, 2024
Letter
Office of Trade & Services United States Securities and Exchange Commission Division of Corporation Finance Re: Evolent Health, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 Item 2.02 Form 8-K filed August 8, 2024 File No. 001-37415
Dear Ms. Franks and Ms. Li:
This letter is to confirm our telephone conversation through counsel with you on October 3, 2024 regarding our request for an extension of time to respond to your comment letter dated September 20, 2024. We are working expeditiously to respond to the comment letter. However, as discussed, we require additional time to prepare a response. As a result, we respectfully request that you allow us to submit our response by October 18, 2024.
If you have any questions about this response or require additional information, please contact me at jpjohnson@evolent.com.
Respectfully submitted,
Evolent Health, Inc.
Show Raw Text
CORRESP 1 filename1.htm Document October 4, 2024 Office of Trade & Services United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attn: Valeria Franks, Suying Li Re: Evolent Health, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 Item 2.02 Form 8-K filed August 8, 2024 File No. 001-37415 Dear Ms. Franks and Ms. Li: This letter is to confirm our telephone conversation through counsel with you on October 3, 2024 regarding our request for an extension of time to respond to your comment letter dated September 20, 2024. We are working expeditiously to respond to the comment letter. However, as discussed, we require additional time to prepare a response. As a result, we respectfully request that you allow us to submit our response by October 18, 2024. If you have any questions about this response or require additional information, please contact me at jpjohnson@evolent.com. Respectfully submitted, Evolent Health, Inc. /s/ John Johnson John Johnson Chief Financial Officer cc: Elizabeth Morgan, King and Spalding LLP